The objectives of this study were to develop a population pharmacokinetic model of prophylactically administered cefazolin in patients undergoing cardiac surgery with and without the use of the cardiopulmonary bypass of both existing types-standard (ECC) and minimallyu invasive extracorporeal circulation (MiECC)-and to propose cefazoline dosing optimization based on this model. A total of 65 adult patients undergoing cardiac surgery were recruited to this clinical trial. A prophylactic cefazolin dose of 2 g was intravenously administered before surgery. Blood samples were collected using a rich sampling design and cefazolin serum concentrations were measured using the HPLC/UV method. The pharmacokinetic population model was calculated using a nonlinear mixed-effects modeling approach, and the Monte Carlo simulation was used to evaluate the PK/PD target attainment. The population cefazolin central volume of distribution (Vd) of 4.91 L increased by 0.51 L with each 1 m2 of BSA, peripheral Vd of 22.07 L was reduced by 0.77 L or 0.79 L when using ECC or MiECC support, respectively, while clearance started at 0.045 L/h and increased by 0.49 L/h with each 1 mL/min/1.73 m2 of eGFR. ECC/MiECC was shown to be covariate of cefazolin Vd, but without relevance to clinical practice, while eGFR was most influential for the PK/PD target attainment. The standard dose of 2 g was sufficient for PK/PD target attainment throughout surgery in patients with normal renal status or with renal impairment. In patients with augmented renal clearance, an additive cefazolin dose should be administered 215, 245, 288 and 318 min after the first dose at MIC of 4, 3, 2 and 1.5 mg/L, respectively.

Department of Cardiac Surgery Faculty of Medicine and Dentistry Palacký University University Hospital Olomouc 779 00 Czech Republic

Department of Pharmacology 1st Faculty of Medicine Charles University General University Hospital Prague 128 00 Czech Republic

Department of Pharmacology Faculty of Medicine and Dentistry Palacký University University Hospital Hněvotínská 3 775 15 Olomouc Czech Republic

See more in PubMed

Lepelletier D., Bourigault C., Roussel J.C., Lasserre C., Leclere B., Corvec S., Pattier S., Lepoivre T., Baron O., Despins P. Epidemiology and prevention of surgical site infections after cardiac surgery. Médecine Mal. Infect. 2013;43:403–409. doi: 10.1016/j.medmal.2013.07.003. PubMed DOI

Soderquist B. Surgical site infections in cardiac surgery: Microbiology. Apmis. 2007;115:1008–1011. doi: 10.1111/j.1600-0463.2007.00833.x. PubMed DOI

Engelman R., Shahian D., Shemin R., Guy T.S., Bratzler D., Edwards F., Jacobs M., Fernando H., Bridges C., Workforce on Evidence-Based Medicine, Society of Thoracic Surgeons practice The Society of Thoracic Surgeons practice guideline series: Antibiotic prophylaxis in cardiac surgery, part II: Antibiotic choice. Ann. Thorac. Surg. 2007;83:1569–1576. doi: 10.1016/j.athoracsur.2006.09.046. PubMed DOI

State Institute for Drug Control of Czech Republic Azepo—Summary of Product Characteristics. [(accessed on 14 August 2022)]. Available online: https://www.sukl.cz/modules/medication/detail.php?code=0016600&tab=texts.

Song H.K., Diggs B.S., Slater M.S., Guyton S.W., Ungerleider R.M., Welke K.F. Improved quality and cost-effectiveness of coronary artery bypass grafting in the United States from 1988 to 2005. J. Thorac. Cardiovasc. Surg. 2009;137:65–69. doi: 10.1016/j.jtcvs.2008.09.053. PubMed DOI

Butler J., Rocker G.M., Westaby S. Inflammatory response to cardiopulmonary bypass. Ann. Thorac. Surg. 1993;55:552–559. doi: 10.1016/0003-4975(93)91048-R. PubMed DOI

Speir A.M., Kasirajan V., Barnett S.D., Fonner E., Jr. Additive costs of postoperative complications for isolated coronary artery bypass grafting patients in Virginia. Ann. Thorac. Surg. 2009;88 doi: 10.1016/j.athoracsur.2009.03.076. PubMed DOI

Anastasiadis K., Bauer A., Antonitsis P., Gygax E., Schaarschmidt J., Carrel T. Minimal invasive Extra-Corporeal Circulation (MiECC): A revolutionary evolution in perfusion. Interact. Cardiovasc. Thorac. Surg. 2014;19:541–542. doi: 10.1093/icvts/ivu304. PubMed DOI

Anastasiadis K., Murkin J., Antonitsis P., Bauer A., Ranucci M., Gygax E., Schaarschmidt J., Fromes Y., Philipp A., Eberle B., et al. Use of minimal invasive extracorporeal circulation in cardiac surgery: Principles, definitions and potential benefits. A position paper from the Minimal invasive Extra-Corporeal Technologies international Society (MiECTiS) Interact. Cardiovasc. Thorac. Surg. 2016;22:647–662. doi: 10.1093/icvts/ivv380. PubMed DOI PMC

Paruk F., Sime F.B., Lipman J., Roberts J.A. Dosing antibiotic prophylaxis during cardiopulmonary bypass-a higher level of complexity? A structured review. Int. J. Antimicrob. Agents. 2017;49:395–402. doi: 10.1016/j.ijantimicag.2016.12.014. PubMed DOI

Lehot J.J., Reverdy M.E., Etienne J., Corot C., Nervi C., Sear J., Fleurette J., Estanove S. Cefazolin and netilmicin serum levels during and after cardiac surgery with cardiopulmonary bypass. J. Cardiothorac. Anesth. 1990;4:204–209. doi: 10.1016/0888-6296(90)90239-C. PubMed DOI

Fellinger E.K., Leavitt B.J., Hebert J.C. Serum levels of prophylactic cefazolin during cardiopulmonary bypass surgery. Ann. Thorac. Surg. 2002;74:1187–1190. doi: 10.1016/S0003-4975(02)03916-4. PubMed DOI

Caffarelli A.D., Holden J.P., Baron E.J., Lemmens H.J., D’Souza H., Yau V., Olcott C.t., Reitz B.A., Miller D.C., van der Starre P.J. Plasma cefazolin levels during cardiovascular surgery: Effects of cardiopulmonary bypass and profound hypothermic circulatory arrest. J. Thorac. Cardiovasc. Surg. 2006;131:1338–1343. doi: 10.1016/j.jtcvs.2005.11.047. PubMed DOI

Kosaka T., Hosokawa K., Shime N., Taniguchi F., Kokufu T., Hashimoto S., Fujiwara H., Yaku H., Sugioka N., Okada K., et al. Effects of renal function on the pharmacokinetics and pharmacodynamics of prophylactic cefazolin in cardiothoracic surgery. Eur. J. Clin. Microbiol. Infect. Dis. 2012;31:193–199. doi: 10.1007/s10096-011-1293-z. PubMed DOI

Lanckohr C., Horn D., Voeller S., Hempel G., Fobker M., Welp H., Koeck R., Ellger B. Pharmacokinetic characteristics and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective cardiac surgery. J. Thorac. Cardiovasc. Surg. 2016;152:603–610. doi: 10.1016/j.jtcvs.2016.04.024. PubMed DOI

Asada M., Nagata M., Mizuno T., Uchida T., Takahashi H., Makita K., Arai H., Kijima S., Echizen H., Yasuhara M. Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass in adult patients undergoing cardiac surgery. Eur. J. Clin. Pharmacol. 2021;77:735–745. doi: 10.1007/s00228-020-03045-1. PubMed DOI

Santavy P., Kubickova V., Sima M., Urbanek K. Population pharmacokinetics of three alternative prophylactic antibiotics during cardiac surgery with extracorporeal circulation. Biomed. Pap. 2022. Online ahead of print . PubMed DOI

Kubickova V., Racova Z., Strojil J., Santavy P., Urbanek K. Separation of ampicillin on polar-endcapped phase: Development of the HPLC method to achieve its correct dosage in cardiac surgery. Acta Chromatogr. 2022. Online ahead of print . DOI

Kubíčková V., Šantavý P., Urbánek K. Determination of ampicillin plasma concentrations in single-dose administration for cardiac surgery prophylaxis. Klin. Farmakol. Farm. 2022;36:4–7. doi: 10.36290/far.2022.001. DOI

European Medicine Agency Guideline on Bioanalytical Method Validation. [(accessed on 14 August 2022)]; Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf.

Naik B.I., Roger C., Ikeda K., Todorovic M.S., Wallis S.C., Lipman J., Roberts J.A. Comparative total and unbound pharmacokinetics of cefazolin administered by bolus versus continuous infusion in patients undergoing major surgery: A randomized controlled trial. Br. J. Anaesth. 2017;118:876–882. doi: 10.1093/bja/aex026. PubMed DOI